Skip Ribbon Commands
Skip to main content

AS630 – Autoantibodies for Small Cell Lung Cancer Early Detection

[This is a template - please replace the text and content of this site with the materials relevant to your ancillary study. Feel free to remove guiding text, like this, contained in brackets]

[This site contains pages, such as this, to describe your study. In addition, pre-created "Document Libraries" (much like file folders on a PC) are set up for the storage of raw and analytical datasets, data dictionaries, data preparation documents, and other relevant study documentation. For help in using the features of this site, along with guidelines for data submission, please consult the Data Submission Guidelines and Help Topics]

AS630 – Autoantibodies for Small Cell Lung Cancer Early Detection


Investigator Names and Contact Information

Paul Lampe [ ]



Small cell lung cancer (SCLC) is one of the few malignancies with such poor outcomes that it meets the definition

of a "recalcitrant" cancer, accounting for 30,000 American lives each year with five-­year survival rates of just

~7%. Somewhat lost in these dismal statistics is the fact that patients diagnosed early (limited stage) display

vastly superior survival metrics when compared to those diagnosed late (extensive stage). Unfortunately, only a

minority of cases are identified at limited stage, and the CT screening approaches capable of early detection for

non-­small cell lung cancer (NSCLC) have not proven effective for SCLC. We employ a novel hybrid plasma

marker panel capable of detecting proteomic and autoantibody markers for SCLC early detection. We have

accumulated very positive discovery and confirmatory data centered around paraneoplastic syndrome (PNS)

autoantibodies using the Cardiovascular Health Study (prediagnostic), Fred Hutch Lung Cancer Early Detection

and Prevention Clinic (LCEDPC), and Vanderbilt SCLC cohort samples. One of the major problems with SCLC

is that there are few studies and cohorts of any size available with plasma as there currently is little ongoing

research due to its intractability. The WHI helpdesk estimates there are 71 SCLC cases diagnosed within 3

years of a blood draw in the observational study (OS) and clinical trial (CT). Thus, we request 250 μl of all of

these samples (baseline and year 3, justified below) plus 2 matched controls to attempt to validate our biomarker

candidates using a nested case-­control design.


Specific Aims:

Specific Aim #1: Validation of autoantibody and proteomic, plasma markers for the early detection of SCLC

Specific Aim #2: Establish the maximal time interval prior to diagnosis that hybrid plasma markers are

capable of identifying SCLC